4//SEC Filing
Fitzgerald Kevin Joseph 4
Accession 0001735276-25-000114
CIK 0001178670other
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 5:13 PM ET
Size
29.6 KB
Accession
0001735276-25-000114
Insider Transaction Report
Form 4
Fitzgerald Kevin Joseph
CSO & EVP, Head of Research
Transactions
- Sale
Common Stock
2025-10-02$448.77/sh−150$67,316→ 27,379 total - Award
Common Stock
2025-10-01+2,851→ 27,672 total - Sale
Common Stock
2025-10-02$449.79/sh−207$93,107→ 27,172 total - Sale
Common Stock
2025-10-02$451.86/sh−276$124,713→ 26,447 total - Sale
Common Stock
2025-10-02$455.82/sh−60$27,349→ 25,356 total - Sale
Common Stock
2025-10-02$457.43/sh−122$55,806→ 25,234 total - Sale
Common Stock
2025-10-02$446.53/sh−96$42,867→ 27,576 total - Sale
Common Stock
2025-10-02$447.92/sh−47$21,052→ 27,529 total - Sale
Common Stock
2025-10-02$450.81/sh−449$202,414→ 26,723 total - Sale
Common Stock
2025-10-02$453.77/sh−273$123,879→ 25,619 total - Award
Common Stock
2025-10-01+2,102→ 24,821 total - Sale
Common Stock
2025-10-02$454.84/sh−203$92,333→ 25,416 total - Sale
Common Stock
2025-10-02$452.69/sh−555$251,243→ 25,892 total - Sale
Common Stock
2025-10-02$457.64/sh−3$1,373→ 25,231 total
Holdings
- 537(indirect: by Managed Account)
Common Stock
Footnotes (14)
- [F1]On February 24, 2021, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of four specified performance measures. The shares reported were issued to the reporting person upon vesting of one-quarter of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study of an RNAi therapeutic in development to treat a prevalent disease, as determined by the People, Culture and Compensation (PC&C) Committee of the Issuer Board of Directors on October 1, 2025.
- [F10]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.33 to $453.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F11]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.37 to $454.37. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F12]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.38 to $455.34. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F13]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.42 to $456.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F14]Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
- [F2]On March 1, 2024, the reporting person was granted a PSU under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study in a prevalent indication, as determined by the PC&C Committee on October 1, 2025.
- [F3]Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024.
- [F4]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $446.19 to $447.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F5]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.21 to $448.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F6]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $448.25 to $449.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F7]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.26 to $450.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F8]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.29 to $451.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F9]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.31 to $452.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Documents
Issuer
ALNYLAM PHARMACEUTICALS, INC.
CIK 0001178670
Entity typeother
Related Parties
1- filerCIK 0001886431
Filing Metadata
- Form type
- 4
- Filed
- Oct 2, 8:00 PM ET
- Accepted
- Oct 3, 5:13 PM ET
- Size
- 29.6 KB